Imakrebin (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By inhibiting these enzymes, it stops downstream signaling that promotes malignant cell growth, leading to cell cycle arrest and apoptosis of the cancerous cells.

The dose of Imakrebin is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should determine the appropriate regimen.

Imakrebin is classified as contraindicated in pregnancy unless the potential benefit justifies the risk, because animal studies have shown fetal harm. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To order Imakrebin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Imakrebin (imatinib) was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and GIST. Newer agents such as dasatinib or nilotinib may offer activity against certain resistant mutations, but imatinib retains a well‑characterized safety profile and extensive clinical experience.

Imakrebin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from excess moisture, direct sunlight and heat to maintain potency throughout its shelf life.

Imakrebin is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should swallow the dose whole and follow any specific instructions regarding timing or concomitant medications.

Serious risks include severe liver toxicity, profound neutropenia or leukopenia, cardiac dysfunction, pulmonary hypertension, and rare but life‑threatening allergic reactions. Patients should be monitored regularly for laboratory abnormalities and clinical signs of these events.

Imakrebin is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. It should also be avoided in patients with uncontrolled infections, severe hepatic impairment, or those taking medications that cause dangerous drug‑drug interactions without appropriate monitoring.